Updated:
Immuron Ltd
Immuron Ltd is an Australian biopharmaceutical company developing oral antibodies for gastrointestinal infections; no evidence of family-office operations.
Immuron Ltd
Immuron Ltd is a publicly traded Australian biopharmaceutical firm (ASX: IMC) that develops oral immunotherapies targeting enteric diseases such as traveler's diarrhea and Clostridium difficile infection. The company's lead product, Travelan, is an over-the-counter oral antibody derived from bovine colostrum. While the firm's name suggests a possible family-office connection, no public disclosures indicate it operates as a family office or asset manager. Based on available information, Immuron appears to be a conventional biotech company, not a capital allocator.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
Is Immuron Ltd a family office or investment firm?
No. Based on public filings and company communications, Immuron Ltd is a biopharmaceutical company listed on the Australian Securities Exchange (ASX: IMC), not a family office or asset manager.
What does Immuron Ltd do?
Immuron develops oral immunotherapies for gastrointestinal infections, including Travelan for traveler's diarrhea and a therapeutic for C. difficile infection. Its products are based on hyperimmune bovine colostrum technology.
Who are Immuron Ltd's key executives?
As of public filings, key personnel include CEO and Managing Director Steven Lydeamore. No named investment principals or family-office-related individuals are disclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: